We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Efficacy of Urinary Follicle-Stimulating Hormone (FSH) Among Poor Responders

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by German Hospital, Istanbul.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: May 14, 2008
Last Update Posted: May 14, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Bahceci Women Health Care Center
Information provided by:
German Hospital, Istanbul
We proposed to compare outcomes in women with DOR undergoing ART with rec-FSH + u-HMH with those with u-FSH only in GnRH antagonist protocols.

Condition Intervention
Infertility Drug: Fostimon

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Urinary Purified Follicle-Stimulating Hormone (FSH) and Rec-FSH Among Poor Responders Undergoing Ovarian Stimulation With GnRH Antagonist

Resource links provided by NLM:

Further study details as provided by German Hospital, Istanbul:

Primary Outcome Measures:
  • pregnancy rate per embryo transfer [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • number of oocytes retrieved [ Time Frame: per patient ]

Study Start Date: May 2008
Estimated Study Completion Date: November 2008
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: UrFSH Drug: Fostimon
450 IU for 4 days then adjusted


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • At least one trial with adequate ovarian stimulation resulted by 4 or less oocytes retrieval.

Exclusion Criteria:

  • High responder patients
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00677573

Contact: Ulun Ulug, M.D. 90-21-2293-2150 ext 14111 ulunulug@superonline.com
Contact: Mustafa Bahceci, M.D 90-21-2230-0809 mbahceci@superonline.com

Alman Hastanesi Not yet recruiting
İstanbul, Turkey
Contact: Haluk Toygarlı, M.D.    90-21-2293-2150      
Principal Investigator: ulun ulug, M.D.         
Sub-Investigator: mustafa bahceci, M.D.         
Sub-Investigator: enver kurt, M.D.         
Sponsors and Collaborators
German Hospital, Istanbul
Bahceci Women Health Care Center
  More Information

Responsible Party: German Hospital, Istanbul
ClinicalTrials.gov Identifier: NCT00677573     History of Changes
Other Study ID Numbers: ughno1
First Submitted: May 9, 2008
First Posted: May 14, 2008
Last Update Posted: May 14, 2008
Last Verified: May 2008

Keywords provided by German Hospital, Istanbul:
poor responder
GnRH antagonist

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs